
# **Deloitte**


## 2018 Global Life Sciences Outlook

Innovating life sciences in the fourth industrial revolution: Embrace, build, grow



## Economic overview and outlook

## Pharma forecast to reach \$1.06 trillion worldwide by 2022



- ← Forecast to reach **\$521.9 billion** by 2022
- $\ominus$  In vitro diagnostics is expected to remain the largest medtech segment
- $\ominus$  By 2022, the top ten companies are expected

Issues that could impact growth?

⊖ Pricing pressures, 2nd patent cliff (estimated **\$194 billion** in sales could be at risk by **2022**)



 $\ominus$  Consolidation in generics markets and increased budgets for high-priced treatments, including orphan drugs (could account for **\$95 billion** in **2022**)

## Spending on R&D slows a bit but still steady (2.4%) until 2022

- Small niche companies, where the majority of new drugs are discovered, appear to be driving innovation.
- Less than a quarter of drugs are being discovered by large pharmaceutical companies.

The orphan drug market is expected to almost **double** in the next five years


Orphan drug approvals 2017 - 75

2016 – **27** 

to make up 37% of the medtech market

2015 - 56





- $\ominus$  Extra capital may now be available to fund additional research, business expansion, job growth and capital expenditures, but some companies may take a conservative approach
- $\bigcirc$  Expected to continue to advocate for policy changes to reduce drug prices
- Medtech is expected to continue to battle excise tax
- Medicines Agency (EMA) will change

## Building an adaptable organization for the future of work

The future of work will be more networked, devolved, mobile, collaborative, team-based, project-based, and fluid

### **Old rules**

Job replaced by machines/AI **Full-time employees** Full-time & skills based Static & fixed skills



New rules

Human skills augmented by tech Contractors, gig employees, etc. Options across workforce & tech **Constant reinvention** 


**Defined career ladders** Robotics & cognitive tech are IT Narrow HR focus on change to automation Focus on 'jobs' & 'job descriptions'

Portfolio of projects/experience Integration of people & tech HR has a strategic role Fundamental elements are 'tasks'

## The challenges:

 $\bigcirc$  The slow rate of adopting new technologies

 $\bigcirc$  Too few understand the impact advanced technologies have, or will have



#### In a skills-based economy, talent will be a differentiator

In addition to new digital and analytical skills, there will be a demand for skills that are essentially human Robotics, AI, sensors and cognitive computing

will result in the redesign of almost every job Connecting on mission, ethics, and

values will be critical

Greater autonomy at team Able to see the big picture Generalists skilled at breaking down silos and bridging knowledge across an organization

## Building a culture of courage to help counter uncertainty

An ethics-driven culture will be a massive focus of regulators in the next few years. Regulators expect the life science sector to be proactive, rather than just react to inquiries or defend themselves.

Proactive cybersecurity, minimizing risk

"security by design" .....incorporating cybersecurity into product life cycle -seen as an increasingly important solution

Cloud security becoming increasingly important



 $\bigcirc$  Patient care and safety

- ⊖ Organizational assets
- $\bigcirc$  Reputation
- $\bigcirc$  Intellectual property
- $\bigcirc$  Relationships with customers
- $\ominus$  Shareholder value
- Regulatory compliance

#### To mitigate cyber security risks, organizations need to be:


- Proactive near and real-time monitoring
- Threat pattern collection
- $\bigcirc$  Cyber threat modeling and analysis
- $\bigcirc$  Threat mitigation and remediation
- $\ominus$  Incident management
- $\bigcirc$  Threat intelligence reporting

## Building data integrity, maximizing the value of data

## Making data reusable and accessible across silos

Creating a working environment that values data integrity. **Data integrity** = complete + consistent + accurate throughout data lifecycle






## **Building patient trust and centricity**

Life science companies are embracing digital technology's potential for advancing patient-centricity


Automated processes and optimized use of digital talent Patient centric corporate culture

### Envisioning the future of connected patient journey of care

- Comprehensive comms platforms
- E-visits & telemedicine
- $\ominus$  Bio-telemetry
- $\ominus$  Quantified self, PHR
- ⊖ Web-based portals for regulatory and patient engagement
- Hospitals designed to support patients



## Building a smart, cross-functional regulatory approach



## Growing through partnerships and new operating models

### **Partnership trends**

- Ontraditional deal-making in strong therapeutic areas
- Strong, harmonious partnerships with regulators
- Symbiotic partnerships with tech giants and startups
- $\ominus$  Collaborative scientific partnerships with life sciences, academia, nonprofits and government  $\ominus$  Clinical partnerships



**Collaborations with tech partners** will become increasingly important to:

Optimize patient treatment regimens,

Manage and analyze increasing amounts of data Improve internal data accessibility to drive better informed decision making



The Chief Innovation Officer will become one of the more important executives in the pharma C-suite, and key to leading fast, focused innovation

#### New operating models Top issues transforming the operating model



Supply Chain organizations that adopt direct to patient distribution models could reduce distribution spend by 15-20%, and improve patient experience



Patient moving from being a **passive** recipient of treatment to becoming a **central part** of the R&D process for new therapies

#### About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms. Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's more than 200,000 professionals are committed to becoming the standard of excellence

Disclaimer

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the "Deloitte Network") is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication

#### About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited

The Deloitte Touche Tohmatsu Limited's life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of todays life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today's environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability